Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of ATG-101 in Advanced Solid Tumors and B-NHL
NCT05490043Phase 1Terminated
- Sponsor
- Antengene
- Start
- Jan 2022
- Primary completion
- Mar 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ATG-101 in solid tumor (advanced stage), metastatic solid tumor and mature B-cell non-Hodgkin lymphoma, sponsored by Antengene. Primary endpoints: Adverse Events at 1 year, Serious Adverse Events at 1 year and 1 more. Started Jan 2022; status: terminated.
02
Drugs
ATG-101
03
Conditions
solid tumor (advanced stage)metastatic solid tumormature B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05490043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05490043.